China Pharma (CPHI)
Market Price (9/14/2026): $0.77 | Market Cap: $31.2 MilSector: Health Care | Industry: Pharmaceuticals
China Pharma (CPHI)
Market Price (9/14/2026): $0.77Market Cap: $31.2 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Diabetes Management, Show more. | Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -162% | Penny stockMkt Price is 0.8 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -112% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -21%, Rev Chg QQuarterly Revenue Change % is -7.5% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3.6%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5.6% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 101% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% High stock price volatilityVol 12M is 807% Key risksCPHI key risks include [1] substantial doubt about its ability to continue as a going concern due to its severe financial condition and high probability of bankruptcy, Show more. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Diabetes Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -162% |
| Penny stockMkt Price is 0.8 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -112% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -21%, Rev Chg QQuarterly Revenue Change % is -7.5% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3.6%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5.6% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 101% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% |
| High stock price volatilityVol 12M is 807% |
| Key risksCPHI key risks include [1] substantial doubt about its ability to continue as a going concern due to its severe financial condition and high probability of bankruptcy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
China Pharma (CPHI) stock has lost about 5% since 5/31/2026 because of the following key factors:
1. Weak underlying financial performance continued to suppress stock value.
China Pharma Holdings, Inc. reported a widened net loss of USD 1.46 million for fiscal Q2 2026 (ended June 30, 2026), compared to a net loss of USD 0.528 million in the prior year's fiscal Q2. Sales also decreased to USD 0.948 million from USD 1.03 million in the same period a year ago. For the first six months of fiscal 2026, the company's net loss expanded to USD 2.6 million, and revenue fell 10.6% to USD 1.93 million. This consistent financial underperformance, characterized by negative profitability and shrinking revenue at an approximate 20% compound annual growth rate over the past 3-5 years, kept sustained upward pressure on the stock from building.
2. Significant equity dilution via a direct offering addressed precarious liquidity but reset market expectations.
In July 2026, China Pharma Holdings completed a registered direct offering, selling 2,500,000 common shares at USD 2.00 per share, which generated gross proceeds of USD 5.0 million (net proceeds of USD 4.43 million). While intended for working capital and general corporate purposes to improve the company's precarious liquidity (which included only about USD 170,000 in cash against over USD 7.2 million in current liabilities), this offering resulted in substantial dilution for existing shareholders, given the issuance of new shares. The news of this offering, particularly the $2.00 pricing, coincided with a sharp 77% intraday stock price collapse in July 2026, effectively capping the stock's valuation at a lower range.
Show more
China Pharma (CPHI) stock has lost about 5% since 5/31/2026 because of the following key factors:
1. Weak underlying financial performance continued to suppress stock value.
China Pharma Holdings, Inc. reported a widened net loss of USD 1.46 million for fiscal Q2 2026 (ended June 30, 2026), compared to a net loss of USD 0.528 million in the prior year's fiscal Q2. Sales also decreased to USD 0.948 million from USD 1.03 million in the same period a year ago. For the first six months of fiscal 2026, the company's net loss expanded to USD 2.6 million, and revenue fell 10.6% to USD 1.93 million. This consistent financial underperformance, characterized by negative profitability and shrinking revenue at an approximate 20% compound annual growth rate over the past 3-5 years, kept sustained upward pressure on the stock from building.
2. Significant equity dilution via a direct offering addressed precarious liquidity but reset market expectations.
In July 2026, China Pharma Holdings completed a registered direct offering, selling 2,500,000 common shares at USD 2.00 per share, which generated gross proceeds of USD 5.0 million (net proceeds of USD 4.43 million). While intended for working capital and general corporate purposes to improve the company's precarious liquidity (which included only about USD 170,000 in cash against over USD 7.2 million in current liabilities), this offering resulted in substantial dilution for existing shareholders, given the issuance of new shares. The news of this offering, particularly the $2.00 pricing, coincided with a sharp 77% intraday stock price collapse in July 2026, effectively capping the stock's valuation at a lower range.
3. Extreme speculative volatility, including a "blow-off top," prevented stable price appreciation.
The stock experienced dramatic, non-fundamental volatility in July 2026, with shares spiking from approximately USD 0.86 to a high of USD 19.19 on July 21, 2026, before rapidly collapsing back towards the USD 1–USD 2 range in subsequent sessions. This pattern was characteristic of a "blow-off top" driven by speculative trading rather than improved business fundamentals. Such extreme price swings, where the stock can move 12% a week, indicate high sensitivity to market sentiment around financing events, preventing the establishment of a stable, fundamentally-driven uptrend for the period.
Show less
Stock Movement Drivers
Fundamental Drivers
The -4.2% change in CPHI stock from 5/31/2026 to 9/13/2026 was primarily driven by a -36.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312026 | 9132026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.79 | 0.76 | -4.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 4 | -1.9% |
| P/S Multiple | 5.1 | 7.9 | 54.6% |
| Shares Outstanding (Mil) | 26 | 41 | -36.8% |
| Cumulative Contribution | -4.2% |
Market Drivers
5/31/2026 to 9/13/2026| Return | Correlation | |
|---|---|---|
| CPHI | -4.2% | |
| Market (SPY) | 1.0% | 12.6% |
| Sector (XLV) | 10.6% | 5.0% |
Fundamental Drivers
The 32.7% change in CPHI stock from 2/28/2026 to 9/13/2026 was primarily driven by a 1336.9% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9132026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.57 | 0.76 | 32.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 4 | -3.4% |
| P/S Multiple | 0.5 | 7.9 | 1336.9% |
| Shares Outstanding (Mil) | 4 | 41 | -90.4% |
| Cumulative Contribution | 32.7% |
Market Drivers
2/28/2026 to 9/13/2026| Return | Correlation | |
|---|---|---|
| CPHI | 32.7% | |
| Market (SPY) | 11.7% | 9.3% |
| Sector (XLV) | 3.6% | 6.3% |
Fundamental Drivers
The -45.3% change in CPHI stock from 8/31/2025 to 9/13/2026 was primarily driven by a -92.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 9132026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.39 | 0.76 | -45.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 4 | -11.0% |
| P/S Multiple | 1.0 | 7.9 | 671.7% |
| Shares Outstanding (Mil) | 3 | 41 | -92.0% |
| Cumulative Contribution | -45.3% |
Market Drivers
8/31/2025 to 9/13/2026| Return | Correlation | |
|---|---|---|
| CPHI | -45.3% | |
| Market (SPY) | 19.5% | 8.0% |
| Sector (XLV) | 21.9% | 4.9% |
Fundamental Drivers
The -90.5% change in CPHI stock from 8/31/2023 to 9/13/2026 was primarily driven by a -99.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312023 | 9132026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.00 | 0.76 | -90.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 4 | -50.7% |
| P/S Multiple | 0.2 | 7.9 | 4525.6% |
| Shares Outstanding (Mil) | 0 | 41 | -99.6% |
| Cumulative Contribution | -90.5% |
Market Drivers
8/31/2023 to 9/13/2026| Return | Correlation | |
|---|---|---|
| CPHI | -90.5% | |
| Market (SPY) | 75.7% | 3.2% |
| Sector (XLV) | 30.0% | 1.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CPHI Return | 8% | -80% | -87% | -62% | -48% | -37% | -100% |
| Peers Return | -11% | -28% | 68% | 11% | 7% | 24% | 61% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| CPHI Win Rate | 42% | 8% | 33% | 42% | 25% | 33% | |
| Peers Win Rate | 44% | 42% | 61% | 47% | 47% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| CPHI Max Drawdown | -68% | -81% | -92% | -74% | -95% | -91% | |
| Peers Max Drawdown | -36% | -43% | -37% | -23% | -40% | -26% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VTRS, AMRX, PRGO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/11/2026 (YTD)
How Low Can It Go
| Event | CPHI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -93.8% | -18.8% |
| % Gain to Breakeven | 1511.1% | 23.1% |
| Time to Breakeven | 34 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -32.1% | -7.8% |
| % Gain to Breakeven | 47.2% | 8.5% |
| Time to Breakeven | 61 days | 18 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -14.0% | -19.2% |
| % Gain to Breakeven | 16.3% | 23.8% |
| Time to Breakeven | 7 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -28.7% | -3.7% |
| % Gain to Breakeven | 40.3% | 3.9% |
| Time to Breakeven | 15 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -52.0% | -12.2% |
| % Gain to Breakeven | 108.3% | 13.9% |
| Time to Breakeven | 118 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -55.1% | -6.8% |
| % Gain to Breakeven | 122.9% | 7.3% |
| Time to Breakeven | 131 days | 15 days |
In The Past
China Pharma's stock fell -93.8% during the 2025 US Tariff Shock. Such a loss loss requires a 1511.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CPHI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -93.8% | -18.8% |
| % Gain to Breakeven | 1511.1% | 23.1% |
| Time to Breakeven | 34 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -32.1% | -7.8% |
| % Gain to Breakeven | 47.2% | 8.5% |
| Time to Breakeven | 61 days | 18 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -28.7% | -3.7% |
| % Gain to Breakeven | 40.3% | 3.9% |
| Time to Breakeven | 15 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -52.0% | -12.2% |
| % Gain to Breakeven | 108.3% | 13.9% |
| Time to Breakeven | 118 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -55.1% | -6.8% |
| % Gain to Breakeven | 122.9% | 7.3% |
| Time to Breakeven | 131 days | 15 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -63.3% | -53.4% |
| % Gain to Breakeven | 172.7% | 114.4% |
| Time to Breakeven | 305 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -21.5% | -8.6% |
| % Gain to Breakeven | 27.4% | 9.5% |
| Time to Breakeven | 8 days | 47 days |
In The Past
China Pharma's stock fell -93.8% during the 2025 US Tariff Shock. Such a loss loss requires a 1511.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About China Pharma (CPHI)
China Pharma Holdings, Inc. (CPHI) is a pharmaceutical company based in the People's Republic of China. The company's core business involves the development, manufacturing, and marketing of a range of generic and branded pharmaceutical products, as well as biochemical products. CPHI primarily serves hospitals and private retailers within the Chinese market, leveraging its extensive sales network.
CPHI's product portfolio is diverse, offered in various forms including dry powder injectables, liquid injectables, tablets, capsules, and oral solutions. Key offerings target a broad spectrum of medical conditions. These include treatments for neurological issues like memory decline and attention deficits (e.g., Cerebroprotein Hydroloysate, Gastrodin injection), cardiovascular diseases such as cerebral thrombosis and coronary heart disease (e.g., Propylgallate, Ozagrel Sodium, Alginic Sodium Diester injection), and conditions like hypertension and edema. The company also provides a variety of antibiotics and anti-infectives for conditions ranging from tonsillitis to respiratory tract infections (e.g., Roxithromycin, Cefaclor, Cefalexin), as well as medications for digestive diseases (e.g., Hepatocyte growth-promoting factor, Omeparzole) and supportive care products like those for chemotherapy-induced nausea.
Beyond its core pharmaceutical line, China Pharma Holdings also offers a Noni Enzyme food supplement, sanitizers, and masks. The company distributes its products across China through a network that includes third-party distributors, 16 company-owned sales offices, and approximately 1,000 sales representatives, ensuring broad market penetration.
AI Analysis | Feedback
A Chinese version of Johnson & Johnson's pharmaceutical division, offering a wide range of generic and branded medicines.
Like GSK (GlaxoSmithKline), but focused on manufacturing and distributing a broad portfolio of pharmaceuticals specifically for the Chinese market.
AI Analysis | Feedback
- Cerebroprotein Hydroloysate injection: Treats memory decline and attention deficit.
- Gastrodin injection: Addresses tiredness, poor sleep, and traumatic syndromes of the brain.
- Propylgallate and Ozagrel Sodium: Used to treat cerebral thrombosis, coronary heart disease, and post-surgery complications.
- Alginic Sodium Diester injection: Targets ischemic heart, cerebrovascular, and high lipoprotein blood diseases.
- Bumetanide injection: Treats various edema diseases.
- Candesartan: A medication primarily used for hypertension.
- Roxithromycin dispersible tablets: An antibiotic for pharyngitis and tonsillitis.
- Cefaclor dispersible tablets: An antibiotic for ear, respiratory, urinary, and skin/skin tissue infections.
- Cefalexin capsules: An antibiotic primarily for acute tonsillitis.
- Andrographolide: Used for sore throat caused by upper respiratory tract infection.
- Clarithromycin granules and capsules: An antibiotic medication.
- Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets: A sustained-release combination for pain relief and decongestion.
- Hepatocyte growth-promoting factor: Used for the treatment of digestive diseases.
- Tiopronin: Used for the treatment of digestive diseases.
- Compound Ammonium Glycyrrhetate S: Used for the treatment of digestive diseases.
- Omeprazole: Used for the treatment of digestive diseases.
- Vitamin B6 injection: A vitamin supplement provided in injectable form.
- Granisetron Hydrochloride injection: Prevents nausea and vomiting caused by radiotherapy and chemotherapy.
- Noni Enzyme: A food supplement.
- Sanitizers: Hygiene products.
- Masks: Personal protective equipment.
AI Analysis | Feedback
China Pharma (CPHI) sells its products primarily to other companies and organizations, not directly to individuals. Based on the provided description, its major customers are:
- Hospitals
- Private retailers
- Distributors
The company description does not provide the specific names of these customer companies or organizations.
AI Analysis | Feedback
null
```AI Analysis | Feedback
China Pharma Holdings, Inc. Management Team
Here is a list of key management team members for China Pharma Holdings, Inc. (CPHI):
Zhilin Li, Chairman, President, Chief Executive Officer, and Interim Chief Financial Officer
Ms. Li co-founded Helpson (Hainan Helpson Medicine & Biotechnique Co., Ltd.), the company's primary operating subsidiary, in 1993, and served as its Chairman and Chief Executive Officer from 1993 to 2005. She has been President and Chief Executive Officer of China Pharma Holdings, Inc. since 2005. Earlier in her career, Ms. Li held positions as the president of Haikou Bio-Engineering Institute and the vice president of Sichuan Institute of Biology. She holds a degree in biology from Sichuan University.
Heung Mei Tsui, Director
Ms. Tsui has been a director of China Pharma Holdings, Inc. since April 28, 2009, and previously served on the board from October 2005 to February 2008. She is a self-employed businesswoman with experience in strategic investments and the pharmaceutical chemical raw material import/export business. Ms. Tsui graduated from Hunan Financial & Economic College in 1982.
Yingwen Zhang, Independent Director
Mr. Zhang joined the board as an independent director in February 2008. He currently serves as a consultant for Shanghai Reseat Medical Tech Co. Ltd., a medical device producer. His past roles include Senior Consultant and Chairman of the HSE (Health Safe and Environment) Committee of SINOFERT Holdings Limited (2005-2009), Commercial Counselor of the China Embassy in Malaysia (2000-2005), and Director-General to Sichuan Provincial Foreign Trade and Economic Cooperation Bureau (1988-2000). Earlier, he served as vice CEO and then CEO of a large state-owned enterprise affiliated with the SINOPEC Group (1983-1988).
G. Michael Bennett, Independent Director
Mr. Bennett has been an independent director since February 2008. He works as an advisor and management consultant for several companies in China, and is also the Chairman of the Board of TALENI Healthcare, Ltd. in California, USA. From 2013 to 2015, he was a part-time CFO for Kang Jia Fu, Royal Traditional Health Investment Management Co. Ltd., and from 2009 to 2013, he was the CEO of American General Business Association.
Baowen Dong, Independent Director
Mr. Dong has served as an independent director since February 2008. From 2003 to 2008, he was part of the expert team at Sichuan University, focusing on teaching evaluation and assessment in Engineering and Medical Science. He has also conducted research on China's Health Care Reform and previously held various teaching and research positions, including dean and professor, at Sichuan University from 1974 to 2001.
AI Analysis | Feedback
The key risks to China Pharma Holdings, Inc. (CPHI) primarily stem from the highly regulated and intensely competitive pharmaceutical market within the People's Republic of China, where the company predominantly operates.
- Stringent and Evolving Regulatory and Healthcare Policy Environment in China: China's pharmaceutical industry is subject to aggressive government intervention aimed at reducing healthcare costs and fostering domestic innovation. Policies such as Volume-Based Procurement (VBP) significantly impact drug pricing, with average price reductions often exceeding 50%, severely squeezing profit margins for pharmaceutical companies like CPHI. The regulatory landscape is continuously evolving, with new policies governing drug development, commercialization, and post-market surveillance. There is also heightened scrutiny of prescribing practices, and serious violations can lead to strict penalties. Furthermore, environmental policies are being used for industrial consolidation, posing existential threats to non-compliant plants.
- Intense Competition in the Chinese Pharmaceutical Market: China Pharma operates in a highly competitive market for both generic and branded pharmaceutical products. The generic drug market, which accounts for a significant share of the Chinese pharmaceutical industry, is characterized by numerous manufacturers competing aggressively on price, leading to low-profit margins compared to international averages. As patents for best-selling drugs expire, the generic market enters new cycles of competition, with drug prices declining with increasing competition. This intense competition, both from domestic rivals and international pharmaceutical majors, makes it challenging to maintain market share and pricing power.
- Significant Dependence on the Chinese Domestic Market and Geopolitical Tensions: China Pharma's operations are almost entirely confined to the People's Republic of China, making the company highly susceptible to the country's economic, political, and regulatory shifts. Broader geopolitical tensions between the U.S. and China also introduce supply chain and market access risks for companies operating within China. While CPHI is a Chinese company, disruptions caused by laws like China's Anti-Espionage Law, which affects supply chains and foreign collaboration, could still indirectly impact its operations or the broader pharmaceutical ecosystem it relies upon.
AI Analysis | Feedback
AI Analysis | Feedback
The addressable markets for China Pharma Holdings, Inc.'s main products and services in the China region are substantial, driven by an aging population, increasing prevalence of various diseases, and growing healthcare awareness.
-
Central Nervous System (CNS) Therapeutics: The China Central Nervous System (CNS) Therapeutics Market is projected to grow from USD 45.7 billion in 2025 to USD 78.5 billion by 2032, registering a Compound Annual Growth Rate (CAGR) of 7.8%.
-
Cardiovascular and Cerebrovascular Drugs: In China, the number of patients with cardiovascular diseases has exceeded 330 million, with the cardiovascular drug market maintaining an annual growth rate of about 7%. Globally, the cardiovascular drugs market was estimated at USD 153.7 billion in 2024 and is expected to reach USD 214.9 billion in 2034, growing at a CAGR of 3.5% from 2025 to 2034.
-
Anti-infectives/Antibiotics: The antibiotics market in China generated a revenue of USD 4,590.4 million in 2024 and is expected to reach USD 6,476.5 million by 2033, demonstrating a CAGR of 3.9% from 2025 to 2033. The infectious disease segment accounted for a significant share of the overall China pharmaceuticals market in 2024.
-
Digestive System Drugs: The Asia Pacific gastrointestinal drugs market was valued at USD 9.1 billion in 2024 and is anticipated to grow at a CAGR of 8.7% from 2025 to 2033, reaching USD 19.28 billion by 2033. China accounted for 28.51% of this regional market share in 2024.
-
Antiemetics: The global antiemetics drugs market size is projected to reach around USD 15.76 billion by 2035, registering a CAGR of 5.33% from 2026 to 2035. The Asia-Pacific region is projected to experience the highest growth rate in this market. The global antiemetics drugs market was valued at USD 7.49 billion in 2023 and is expected to grow at a CAGR of 5.98% from 2024 to 2030.
-
Over-the-Counter (OTC) Drugs (including pain/cold relief): The over-the-counter drugs market in China was valued at USD 21.92 billion in 2024 and is estimated to reach USD 38.06 billion by 2033, with a CAGR of 6.32% from 2025 to 2033. Another estimate places the China OTC Pharmaceuticals Market size at USD 32.20 billion in 2023, projected to reach nearly USD 51.77 billion by 2030 with a CAGR of 7.02%.
-
Medical Disposables (including sanitizers and masks): The China medical disposables market generated a revenue of USD 22,356.2 million in 2023 and is expected to reach USD 72,332.8 million by 2030, growing at a CAGR of 18.3% from 2024 to 2030. This market segment includes disposable masks and hand sanitizers.
AI Analysis | Feedback
China Pharma Holdings, Inc. (CPHI) is expected to drive future revenue growth over the next 2-3 years through several key initiatives, focusing on new product introductions, strategic acquisitions, and optimized market access within China.
Here are 3-5 expected drivers of future revenue growth:
- Growth in sales of the Dry Eye Disease Therapeutic Device: China Pharma Holdings anticipated launching its patented Dry Eye Disease Therapeutic Device in China by the first quarter of 2025. Given the substantial market for dry eye disease in China, projected to reach $579.51 million by 2030, successful market penetration and increasing sales of this device are expected to be a significant revenue driver.
- Development and commercialization of products from newly acquired patents, such as Topiroxostat Nanoemulsion: In February 2026, China Pharma's subsidiary moved to acquire an invention patent for Topiroxostat Nanoemulsion and its preparation method. This acquisition aims to enhance the company's product research and development capabilities and expand its intellectual property and product pipeline. Successful development, regulatory approval, and launch of new pharmaceutical products stemming from such acquisitions are expected to contribute to future revenue growth.
- Leveraging the Hainan Free Trade Port policies and e-prescription platforms for expanded market access: The company has identified new policy measures supporting the Hainan Free Trade Port, including the establishment of an e-prescription center and increased access for market drugs, as opportunities to stimulate growth. China Pharma signed an agreement with an Internet hospital in 2021 to capitalize on these policy changes, indicating a strategic effort to expand sales channels and reach more customers.
- Introduction of new pharmaceutical products from its diversified and growing pipeline: China Pharma Holdings consistently aims to gain competitive advantages by developing a growing pipeline of new pharmaceutical products for specifically targeted patient groups. This ongoing strategy involves introducing new formulations and expanding its portfolio in therapeutic areas such as cardiovascular, central nervous system, infectious, and digestive diseases.
AI Analysis | Feedback
Share Issuance
- In December 2024, China Pharma announced an "at-the-market" equity offering, allowing the company to sell up to $600,000 worth of common stock through December 31, 2024.
- In March 2026, China Pharma's wholly-owned subsidiary agreed to acquire an invention patent for $6.93 million, with the payment to be made by issuing 12,600,000 restricted shares of common stock at $0.55 per share.
Inbound Investments
- China Pharma completed the full redemption of a Convertible Promissory Note with a principal amount of $5,250,000 issued to Streeterville Capital on November 17, 2021, by December 11, 2024.
Peer Outperformance in Pharmaceuticals
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 7.1% | 86.3% | 123.6% | CAH 402% · MCK 343% · COR 175% |
| Managed Health Care | 8 | 43.7% | -1.3% | 8.2% | OSCR 84% · HQY 57% · ELV 23% |
| Health Care Services | 20 | 18.9% | 44.9% | 0.0% | HIMS 218% · RDNT 172% · DGX 67% |
| Health Care Facilities | 24 | 3.7% | 7.9% | -14.2% | NHC 276% · THC 268% · ENSG 122% |
| Health Care Equipment | 50 | -1.7% | -5.5% | -25.7% | POCI 10800% · UFPT 331% · GKOS 234% |
| Health Care Supplies | 12 | 20.8% | -12.1% | -37.9% | LNTH 308% · HAE 51% · MMSI 21% |
| Pharmaceuticals ← | 62 | -7.4% | 7.7% | -40.7% | LQDA 2457% · INDV 1136% · ETON 1063% |
| Life Sciences Tools & Services | 109 | -1.4% | -25.5% | -71.2% | SNWV 1573% · MEDP 224% · NTRA 174% |
| Health Care Technology | 20 | -31.7% | -52.2% | -78.5% | SPOK 77% · HSTM 3% · VEEV -12% |
| Biotechnology | 362 | 1.6% | -24.8% | -79.6% | DNTH 1632% · CELZ 1272% · ELVN 1222% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| China Pharma Stock Dropped 17% - Have You Assessed the Risk | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 15.09 |
| Mkt Cap | 3.7 |
| Rev LTM | 3,631 |
| Op Inc LTM | 190 |
| FCF LTM | 60 |
| FCF 3Y Avg | 172 |
| CFO LTM | 198 |
| CFO 3Y Avg | 285 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.1% |
| Rev Chg 3Y Avg | -2.7% |
| Rev Chg Q | 0.9% |
| QoQ Delta Rev Chg LTM | 0.2% |
| Op Inc Chg LTM | -31.6% |
| Op Inc Chg 3Y Avg | 0.5% |
| Op Mgn LTM | 3.5% |
| Op Mgn 3Y Avg | 5.4% |
| QoQ Delta Op Mgn LTM | -0.6% |
| CFO/Rev LTM | 5.6% |
| CFO/Rev 3Y Avg | 8.2% |
| FCF/Rev LTM | 1.2% |
| FCF/Rev 3Y Avg | 4.9% |
Price Behavior
| Market Price | $0.76 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 04/17/2002 | |
| Distance from 52W High | -90.6% | |
| 50 Days | 200 Days | |
| DMA Price | $1.17 | $0.97 |
| DMA Trend | down | up |
| Distance from DMA | -35.0% | -21.8% |
| 3M | 1YR | |
| Volatility | 1,629.0% | 813.3% |
| Downside Capture | 1024.80 | 450.82 |
| Upside Capture | 952.99 | 269.90 |
| Correlation (SPY) | 14.2% | 8.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.25 | 30.80 | 15.15 | 7.65 | 5.08 | 1.53 |
| Up Beta | 2.78 | 37.41 | 16.79 | 5.11 | 6.25 | 1.05 |
| Down Beta | 3.58 | -8.05 | -2.41 | -0.14 | 0.53 | 3.22 |
| Up Capture | -265% | 4163% | 2288% | 2266% | 804% | 329% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 8 | 17 | 27 | 54 | 110 | 346 |
| Down Capture | 93% | 844% | 460% | 291% | 192% | 113% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 11 | 23 | 35 | 70 | 136 | 398 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CPHI | |
|---|---|---|---|---|
| CPHI | -59.8% | 810.0% | 0.79 | - |
| Sector ETF (XLV) | 22.1% | 16.2% | 1.04 | 4.9% |
| Equity (SPY) | 18.3% | 12.8% | 1.03 | 8.2% |
| Gold (GLD) | 19.0% | 29.2% | 0.59 | 7.1% |
| Commodities (DBC) | 48.3% | 20.6% | 1.80 | 7.3% |
| Real Estate (VNQ) | 7.6% | 13.6% | 0.29 | -0.1% |
| Bitcoin (BTCUSD) | -32.4% | 43.8% | -0.77 | 6.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CPHI | |
|---|---|---|---|---|
| CPHI | -70.7% | 567.2% | 0.41 | - |
| Sector ETF (XLV) | 5.5% | 15.2% | 0.18 | 1.9% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | 3.6% |
| Gold (GLD) | 18.7% | 18.8% | 0.81 | 4.3% |
| Commodities (DBC) | 11.4% | 19.5% | 0.46 | 3.6% |
| Real Estate (VNQ) | 0.7% | 18.9% | -0.07 | 3.2% |
| Bitcoin (BTCUSD) | 9.4% | 52.6% | 0.36 | 2.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CPHI | |
|---|---|---|---|---|
| CPHI | -39.7% | 412.4% | 0.40 | - |
| Sector ETF (XLV) | 10.4% | 16.7% | 0.50 | 2.7% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 4.0% |
| Gold (GLD) | 12.3% | 16.3% | 0.62 | 3.8% |
| Commodities (DBC) | 8.7% | 18.1% | 0.39 | 3.6% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 3.0% |
| Bitcoin (BTCUSD) | 63.2% | 66.2% | 1.03 | 2.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 04/01/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 04/01/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/13/2021 | 10-Q |
| 03/31/2021 | 05/14/2021 | 10-Q |
| 12/31/2020 | 03/26/2021 | 10-K |
| 09/30/2020 | 11/13/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 03/30/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Pharmaceuticals Resources |
| Fierce Pharma |
| Pharm Exec |
| Endpoints News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.